| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 4
| Issue : 1 | Page : 51-55 |
|
|
Soluble HLA-G: A novel marker in acute myeloid leukemia patients
Nahla Abdel Moneim Hamed1, Nabil El Halawani1, Dalia Nafea1, Mohamed Abd El Rahman2, Ahmed Kasber3
1 Department of Clinical Haematology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2 Department of Clinical Pathology, Military Medical Academy, Alexandria, Egypt
3 Department of Clinical Haematology, Military Medical Academy, Alexandria, Egypt
Correspondence Address:
Nahla Abdel Moneim Hamed
Department of Clinical Haematology, Faculty of Medicine, Alexandria University, Alexandria
Egypt
 Source of Support: None, Conflict of Interest: None
DOI: 10.5530/ami.2017.4.10
|
|
|
Objective: to study soluble HLA-G (sHLA-G) in Egyptian acute myeloid leukemia (AML) patients. HLA-G is speculated to be a tumor-driven immune escape mechanism. In addition, it might be a promising target for future immune therapeutic approaches.
Methods: Thirty AML patients and 15 healthy controls of matched age and sex were the subject of the study. sHLA-G was done to all patients and controls by ELISA.
Results: Statistically significant increase in sHLA-G level was present in AML patients compared to controls, being higher in relapsed cases. HLA-G levels was correlated to bone marrow blast percentages but not affected by age, gender, WBCs or response to chemotherapy. HLA-G had a sensitivity of 100% and a specificity of 62% to detect AML cases.
Conclusion: HLA-G may be an additional marker for AML especially relapsed cases
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
